Several authors have highlighted different clinical and immunological phenotypes of these gliptin-associated BPs: mucosal involvement (15), non-inflammatory lesions (18, 23), and target BP180 epitopes outside the NC16A domain (18, 23). The gene discussed is COL17A1; the disease is Bartsocas-Papas syndrome 1.